After receiving a bachelor’s degree from Baylor University, Dr. McCullough completed his medical degree as an Alpha Omega Alpha graduate from the University of Texas Southwestern Medical School in Dallas. He went on to complete his internal medicine residency at the University of Washington in Seattle, cardiology fellowship including service as Chief Fellow at William Beaumont Hospital, and master’s degree in public health at the University of Michigan. Dr. McCullough is a consultant cardiologist and Vice Chief of Medicine at Baylor University Medical Center in Dallas, TX. He is a Principal Faculty in internal medicine for the Texas A & M University Health Sciences Center. Dr. McCullough is an internationally recognized authority on the role of chronic kidney disease as a cardiovascular risk state with > 1000 publications and > 500 citations in the National Library of Medicine. His works include the “Interface between Renal Disease and Cardiovascular Illness” in Braunwald’s Heart Disease Textbook. Dr. McCullough is a recipient of the Simon Dack Award from the American College of Cardiology and the International Vicenza Award in Critical Care Nephrology for his scholarship and research. Dr. McCullough is a founder and current president of the Cardiorenal Society of America, an organization dedicated to bringing cardiologists and nephrologists together to work on the emerging problem of cardiorenal syndromes. His works have appeared in the New England Journal of Medicine, Journal of the American Medical Association, Lancet, British Medical Journal and other top-tier journals worldwide. He is the co-editor of Cardiorenal Medicine, Reviews in Cardiovascular Medicine, and associate editor of the American Journal of Cardiology. He serves on the editorial boards of multiple specialty journals. Dr. McCullough has made presentations on the advancement of medicine across the world and has been an invited lecturer at the New York Academy of Sciences, the National Institutes of Health, U.S. Food and Drug Administration (FDA), European Medicines Agency, and the U.S. Congressional Oversight Panel.
General Statement of Disclosure:
NOTHING TO DISCLOSE